Liver Cancer
Overview
Liver Cancer is a scientific journal, published since 2012 in English. The journal's country of origin is Switzerland.
Details
Details
Abbr.
Liver Cancer
Start
2012
End
Continuing
Frequency
Quarterly
p-ISSN
2235-1795
e-ISSN
1664-5553
Country
Switzerland
Language
English
Metrics
Metrics
h-index / Ranks: 6577
56
SJR / Ranks: 442
3599
CiteScore / Ranks: 502
16.90
JIF / Ranks: 255
13.8
Recent Articles
1.
Liver Cancer
. 2025 Jan;
13(6):674.
PMID: 39780939
[This corrects the article DOI: 10.1159/000537686.].
2.
Park S, Koo B, Jeong B, Choi S, Lee J
Liver Cancer
. 2024 Dec;
13(6):629-642.
PMID: 39687042
Introduction: The Liver Imaging Reporting and Data System (LI-RADS) categorization has been proposed as a potential prognostic indicator for primary liver neoplasms in patients with liver cirrhosis or chronic hepatitis...
3.
Kim K, Kim K, Ryoo B, Choi W, Cha W, Kang M, et al.
Liver Cancer
. 2024 Dec;
13(6):610-628.
PMID: 39687041
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with treatment outcomes closely tied to liver function. This study evaluates the prognostic utility of the albumin-bilirubin (ALBI)...
4.
Song Y, Yeom K, Jung E, Kim S, Kim Y, Yoo J
Liver Cancer
. 2024 Dec;
13(6):590-600.
PMID: 39687040
Introduction: The combination of atezolizumab/bevacizumab has emerged as an effective first-line treatment for advanced hepatocellular carcinoma (HCC). However, this therapy is potentially associated with bleeding complications, warranting a comprehensive analysis...
5.
Hatanaka T, Hiraoka A, Tada T, Kakizaki S
Liver Cancer
. 2024 Dec;
13(6):669-670.
PMID: 39687039
No abstract available.
6.
Singal A, Chhatwal J, Parikh N, Tapper E
Liver Cancer
. 2024 Dec;
13(6):643-654.
PMID: 39687038
Introduction: Given suboptimal performance of ultrasound-based surveillance for early hepatocellular carcinoma (HCC) detection in patients with cirrhosis, there is interest in alternative surveillance strategies, including blood-based biomarkers. We aimed to...
7.
8.
Finn R, Galle P, Ducreux M, Cheng A, Reilly N, Nicholas A, et al.
Liver Cancer
. 2024 Dec;
13(6):655-668.
PMID: 39687036
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations...
9.
Kudo M, Tsuchiya K, Yamashita T, Koga H, Nakagawa Y, Ikeda M
Liver Cancer
. 2024 Dec;
13(6):671-673.
PMID: 39687035
No abstract available.
10.
Shindoh J, Kawamura Y, Akahoshi K, Matsumura M, Okubo S, Akuta N, et al.
Liver Cancer
. 2024 Dec;
13(6):601-609.
PMID: 39687034
Introduction: Introduction of new systemic therapies for hepatocellular carcinoma (HCC) has led to the development of new oncological criteria of resectability for the resectability of HCC. This study was aimed...